Access to Medication Abortion: Now More Important Than Ever.

IF 0.5 4区 社会学 Q3 LAW
Rebecca Fliegel
{"title":"Access to Medication Abortion: Now More Important Than Ever.","authors":"Rebecca Fliegel","doi":"10.1017/amj.2022.24","DOIUrl":null,"url":null,"abstract":"In 2017, 39% of all abortions in the United States were medication abortions, a safe and effective option for those seeking abortions through up to ten weeks of pregnancy.2 The United States Food and Drug Administration (FDA) approved medication abortion, composed of a combination of mifepristone and misoprostol, in 2000, making the method available for the first time.3 The FDA’s choice to approve medication abortion gave abortion activists hope that abortion would bemore readily accessible.4 One of the many barriers to abortion is the social outing one must undertake when visiting a doctor’s office to obtain the procedure—visits often accompanied by protestors outside those offices shouting at the patient. Medication abortion allows for patients to essentially perform their abortions privately, in their own homes, without suffering that social condemnation.5 However, starting in 2004, numerous states began restricting access to medication abortion.6 Many states require that medication abortion only be prescribed and administered7 by a physician who is in the same room as the patient, which essentially prevents physician assistants or advanced practice nurses from prescribing the medication, and any clinician from prescribing and administering the medication via telemedicine.8 These restrictions became problematic during the COVID-19 pandemic when doctors’ offices were either closed or dangerous places to visit for people with certain health conditions.9","PeriodicalId":7680,"journal":{"name":"American Journal of Law & Medicine","volume":"48 2-3","pages":"286-304"},"PeriodicalIF":0.5000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Law & Medicine","FirstCategoryId":"90","ListUrlMain":"https://doi.org/10.1017/amj.2022.24","RegionNum":4,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"LAW","Score":null,"Total":0}
引用次数: 1

Abstract

In 2017, 39% of all abortions in the United States were medication abortions, a safe and effective option for those seeking abortions through up to ten weeks of pregnancy.2 The United States Food and Drug Administration (FDA) approved medication abortion, composed of a combination of mifepristone and misoprostol, in 2000, making the method available for the first time.3 The FDA’s choice to approve medication abortion gave abortion activists hope that abortion would bemore readily accessible.4 One of the many barriers to abortion is the social outing one must undertake when visiting a doctor’s office to obtain the procedure—visits often accompanied by protestors outside those offices shouting at the patient. Medication abortion allows for patients to essentially perform their abortions privately, in their own homes, without suffering that social condemnation.5 However, starting in 2004, numerous states began restricting access to medication abortion.6 Many states require that medication abortion only be prescribed and administered7 by a physician who is in the same room as the patient, which essentially prevents physician assistants or advanced practice nurses from prescribing the medication, and any clinician from prescribing and administering the medication via telemedicine.8 These restrictions became problematic during the COVID-19 pandemic when doctors’ offices were either closed or dangerous places to visit for people with certain health conditions.9
获得药物流产:现在比以往任何时候都更重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
16.70%
发文量
8
期刊介绍: desde Enero 2004 Último Numero: Octubre 2008 AJLM will solicit blind comments from expert peer reviewers, including faculty members of our editorial board, as well as from other preeminent health law and public policy academics and professionals from across the country and around the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信